1. Home
  2. CRDO vs UTHR Comparison

CRDO vs UTHR Comparison

Compare CRDO & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Credo Technology Group Holding Ltd

CRDO

Credo Technology Group Holding Ltd

HOLD

Current Price

$189.64

Market Cap

32.2B

Sector

Technology

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$573.35

Market Cap

25.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRDO
UTHR
Founded
2008
1996
Country
Cayman Islands
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.2B
25.1B
IPO Year
2022
1999

Fundamental Metrics

Financial Performance
Metric
CRDO
UTHR
Price
$189.64
$573.35
Analyst Decision
Strong Buy
Buy
Analyst Count
14
14
Target Price
$179.62
$567.57
AVG Volume (30 Days)
6.4M
544.7K
Earning Date
06-01-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
261.11
13.07
EPS
1.62
27.86
Revenue
$436,775,000.00
$1,483,300,000.00
Revenue This Year
$210.92
$6.39
Revenue Next Year
$57.22
$14.18
P/E Ratio
$111.85
$20.62
Revenue Growth
126.34
2.38
52 Week Low
$40.18
$272.18
52 Week High
$213.80
$607.89

Technical Indicators

Market Signals
Indicator
CRDO
UTHR
Relative Strength Index (RSI) 78.03 57.75
Support Level $129.63 $464.92
Resistance Level $193.50 $607.89
Average True Range (ATR) 10.29 14.38
MACD 8.01 -2.11
Stochastic Oscillator 96.52 58.10

Price Performance

Historical Comparison
CRDO
UTHR

About CRDO Credo Technology Group Holding Ltd

Credo Technology Group Holding Ltd delivers high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. It provides secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. It has a geographic presence in Hong Kong, the United States, Mainland China, Taiwan, and the Rest of the World.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: